Animal experiments reveal that FLA intervention significantly activates the intestinal FXR-FGFR4-CYP7A1 to lower lipid and modulate TGR5-TLR4-TNFα pathways to alleviate inflammation in HFD-induced MASLD [133]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.